Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Revolution Medicines, Inc. (RVMD) provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed late-stage clinical oncology company, Revolution Medicines uses these filings to report on its financial condition, clinical and regulatory milestones, and significant corporate agreements related to its RAS(ON) inhibitor pipeline.
Investors reviewing RVMD’s filings will find current reports on Form 8-K that describe material events such as clinical data updates, FDA designations and strategic financings. For example, the company has filed 8-Ks detailing Breakthrough Therapy Designation and a Commissioner’s National Priority Voucher for daraxonrasib, pipeline updates in pancreatic ductal adenocarcinoma and non-small cell lung cancer, and a Royalty Purchase Agreement with Royalty Pharma covering potential future net product sales of daraxonrasib and zoldonrasib.
Other 8-K filings discuss term loan facilities linked to regulatory approvals and sales milestones, leadership changes at the board and executive levels, and the listing of Revolution Medicines’ common stock (RVMD) and warrants (RVMDW) on The Nasdaq Stock Market LLC. Periodic filings such as Forms 10-Q and 10-K, referenced in the company’s forward-looking statements, provide more comprehensive discussions of risk factors, research and development activities, and overall business strategy.
On Stock Titan, these SEC filings are presented with real-time updates from EDGAR and AI-powered summaries that highlight key points, such as how financing agreements relate to daraxonrasib and zoldonrasib, or what new clinical or regulatory information is disclosed. Users can quickly identify items related to quarterly results (10-Q), annual reports (10-K), and current reports (8-K), as well as monitor registered securities like RVMD and RVMDW.
This page helps readers understand how Revolution Medicines reports on its RAS(ON) inhibitor programs, financial position and significant corporate events through its SEC disclosures, with AI tools simplifying navigation of complex oncology and financing information.
Revolution Medicines, Inc. officer Wang Xiaolin reported an open-market sale of 2,010 shares of common stock on March 17, 2026 at an average price of $99.4804 per share. The transaction was executed under a pre-arranged Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs. Following the sale, Wang holds 116,063 shares directly, including 48,700 restricted stock units.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to proposed sales of restricted stock units tied to RVMD stock. The filing lists a sale method and shows prior sales by Jeffrey Todd Cislini of 2,053 shares on 03/16/2026 and 908 shares on 01/21/2026.
RVMD filed a Form 144 reporting a proposed sale of Common Stock. The notice lists restricted stock unit grants dated 03/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025 with line-item amounts shown in the excerpt. The filing is a routine sale notice; timing and proceeds treatment are not provided in the excerpt.
ETRADE Financial Corporation submitted a Form 144 notice reporting Common Stock related to restricted stock unit grants and prospective sales. The excerpt lists grant dates and awarded share counts: 05/01/2023 1,307 shares; 03/01/2024 464 shares; 03/01/2025 517 shares. The filing references NASDAQ and a date of 03/16/2026.
Stephen Michael Kelsey reported a proposed/recorded sale of 5,447 shares of Common Stock on 12/16/2025 for $418,423.29. The filing also lists restricted stock unit grants dated 03/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025 with counts 910, 937, 1,193, and 861, respectively.
Margaret A. Horn filed a Form 144 reporting sales of Common Stock. The filing lists a sale of $372,333.45 for 4,847 shares on 12/16/2025 and a sale of $7,542,022.50 for 75,000 shares on 01/07/2026. The excerpt also lists restricted stock unit grants dated 03/01/2022 (1,234 units), 03/01/2023 (1,273 units), 03/01/2024 (1,305 units) and 03/01/2025 (910 units).
Revolution Medicines reported insider sales of Common Stock by Mark A. Goldsmith. The filing lists a sale of 15,394 shares on 12/16/2025 for $1,182,525.52 and three sales on 03/02/2026 of 3,000 shares for $303,792.60, 3,000 shares for $303,984.90, and 30,000 shares for $3,036,576.00.
The filing also lists restricted stock unit grants dated 03/01/2022 (3,488 shares), 03/01/2023 (3,488 shares), 03/01/2024 (3,018 shares), and 03/01/2025 (3,267 shares) under issuer grants.
Revolution Medicines: Form 144 notice of proposed resale of Common Stock by an affiliate. The filing lists past sales by Jeff Cislini of $206,483.83 for 2,688 shares on 12/16/2025 and $104,964.80 for 908 shares on 01/21/2026. The record also lists historic restricted stock unit grants of 219, 222, 548, 521, and 543 shares on various grant dates; these grant counts are shown as award history.
Revolution Medicines insider sale reported. The filing lists sales by Jack Anders of 3,104 shares on 12/16/2025 and 10,000 shares on 01/07/2026, with reported proceeds of $239,288.60 and $980,000.00 respectively.
The notice also lists historical restricted stock unit grants with grant dates of 03/01/2022, 09/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025, showing grant quantities of 261, 225, 597, 593, and 458 shares.
Revolution Medicines, Inc. director Elizabeth M. Anderson reported two bona fide gifts of common stock totaling 30,000 shares. The gifts, coded as "G" transactions, occurred on March 4, 2026 at a reported price of $0.00 per share, indicating non-cash charitable or personal transfers.
After these transactions, Anderson holds 8,215 shares directly and 26,990 shares indirectly. The indirect holdings include 3,142 restricted stock units and shares held by trusts, including the Irrevocable Deed of Trust of David W. Anderson and Elizabeth M. Anderson and the David W. Anderson 1996 Irrevocable Trust.